---
figid: PMC3142564__nihms212276f3a
figtitle: Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
organisms:
- Homo sapiens
- Mus musculus
- Saccharomyces cerevisiae
- Drosophila melanogaster
- NA
pmcid: PMC3142564
filename: nihms212276f3a.jpg
figlink: /pmc/articles/PMC149053/figure/fig7/
number: F3a
caption: Figure 3a. Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer.
  Inhibitors targeting major nodes of the PI3K signaling pathway, including RTKs,
  PI3K, AKT and mTOR, have reached clinical trials. Dual inhibitors targeting both
  PI3K and RTK or PI3K and mTOR (as shown in connected solid and dashed lines) may
  provide more potent therapeutic effects in suppressing the PI3K signaling. Combinations
  of PI3K and Raf/MAPK inhibitors may achieve more effective clinical results. mTOR,
  mammalian target of rapamycin; RTK, receptor tyrosine kinase; EGFR, epidermal growth
  factor receptor; Erbb2, Epidermal growth factor Receptor 2; c-Met, mesenchymal-epithelial
  transition factor Ras, a small GTPase protein, Raf, a serine/threonine kinase; MEK,
  mitogen-activated protein kinase kinase; ERK, extracellular signal regulated kinase.Figure
  3b. Inhibitors in clinical development that target the PI3K or related pathways.
  EGFR, epidermal growth factor receptor; Erbb2, Human Epidermal growth factor Receptor
  2; VEGFR, vascular endothelial growth factor receptor; RTK, receptor tyrosine kinase;
  mTOR, mammalian target of rapamycin. *Bevacizumab targets VEGF-A instead of VEGFR
  directly. **Both AZD8055 and OSI027 are ATP-competitive mTOR inhibitors that targets
  both mTORC1 and mTORC2.
papertitle: Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer.
reftext: Pixu Liu, et al. Nat Rev Drug Discov. ;8(8):627-644.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.962016
figid_alias: PMC3142564__F3a
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC3142564__F3a
ndex: 018c6b5d-dec3-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3142564__nihms212276f3a.html
  '@type': Dataset
  description: Figure 3a. Targeting the phosphoinositide 3-kinase (PI3K) pathway in
    cancer. Inhibitors targeting major nodes of the PI3K signaling pathway, including
    RTKs, PI3K, AKT and mTOR, have reached clinical trials. Dual inhibitors targeting
    both PI3K and RTK or PI3K and mTOR (as shown in connected solid and dashed lines)
    may provide more potent therapeutic effects in suppressing the PI3K signaling.
    Combinations of PI3K and Raf/MAPK inhibitors may achieve more effective clinical
    results. mTOR, mammalian target of rapamycin; RTK, receptor tyrosine kinase; EGFR,
    epidermal growth factor receptor; Erbb2, Epidermal growth factor Receptor 2; c-Met,
    mesenchymal-epithelial transition factor Ras, a small GTPase protein, Raf, a serine/threonine
    kinase; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal
    regulated kinase.Figure 3b. Inhibitors in clinical development that target the
    PI3K or related pathways. EGFR, epidermal growth factor receptor; Erbb2, Human
    Epidermal growth factor Receptor 2; VEGFR, vascular endothelial growth factor
    receptor; RTK, receptor tyrosine kinase; mTOR, mammalian target of rapamycin.
    *Bevacizumab targets VEGF-A instead of VEGFR directly. **Both AZD8055 and OSI027
    are ATP-competitive mTOR inhibitors that targets both mTORC1 and mTORC2.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Tie
  - Ras85D
  - InR
  - ras
  - Ras64B
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Mtor
  - Tor
  - Erk7
  - rl
  - Erbb2
  - Met
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Zhx2
  - Akt1
  - Mdk
  - Ephb2
  - Mapk1
  - ERBB2
  - MET
  - EGFR
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
